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INTRODUCTION
Lymphomatoid granulomatosis (LG) is a rare, aggressive, 
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Objective: Lymphomatoid granulomatosis (LG) is a rare, aggressive extranodal Epstein-Barr virus (EBV)-positive B-cell 
lymphoproliferative disease. The purpose of our study was to analyze the CT and fluorodeoxyglucose positron emission 
tomography (FDG-PET) findings of pulmonary LG. 
Materials and Methods: Between 2000 and 2009, four patients with pathologically proven pulmonary LG and chest CT were 
identified. Two of these patients also had FDG-PET. Imaging features of LG on CT and PET were reviewed.
Results: Pulmonary nodules or masses with peribronchovascular, subpleural, and lower lung zonal preponderance were 
present in all patients. Central low attenuation (4 of 4 patients), ground-glass halo (3 of 4 patients), and peripheral 
enhancement (4 of 4 patients) were observed in these nodules and masses. An air-bronchogram and cavitation were seen in 
three of four patients. FDG-PET scans demonstrated avid FDG uptake in the pulmonary nodules and masses.
Conclusion: Pulmonary LG presents with nodules and masses with a lymphatic distribution, as would be expected for a 
lymphoproliferative disease. However, central low attenuation, ground-glass halo and peripheral enhancement of the 
nodules/masses are likely related to the angioinvasive nature of this disease. Peripheral enhancement and ground-glass 
halo, in particular, are valuable characteristic not previously reported that can help radiologists suggest the diagnosis of 
pulmonary LG.
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angiodestructive, extranodal Epstein-Barr virus (EBV)-
positive B-cell lymphoproliferative disease with reactive 
T-cells (1). Reactive T-cells often predominate in the 
background, and therefore, LG was first thought to be a 
T-cell disorder. First described in 1972, LG was initially 
categorized as a subset of pulmonary granulomatous 
vasculitis (2). Prior names for LG include angiocentric 
lymphoma and angiocentric immunoproliferative lesion, 
which reflect the vascular-centered morphology of abnormal 
cells on pathology.
Though the imaging appearance of LG on chest 
radiography has been described in multiple series, the CT 
appearance of pulmonary LG has not been well delineated 
(3-6). To our knowledge, only one other cases series has Korean J Radiol 12(6), Nov/Dec 2011 kjronline.org 672
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studied the CT appearance of pulmonary LG (7). Most 
descriptions of CT and fluorodeoxyglucose positron emission 
tomography (FDG-PET) appearance of LG were presented in 
isolated case reports (8-10). The purpose of our study was 
to analyze the CT and FDG-PET findings in patients with 
pathologically proven pulmonary LG.
MATERIALS AND METHODS
A retrospective review of patient data and of radiological 
studies was approved by our Institutional Review Board. 
No patient consent was required for this Health Insurance 
Portability and Accountability Act (HIPAA)-compliant study. 
Between 2000 and 2009, four patients with pathologically 
proven pulmonary LG and chest CT scans within two weeks 
of pathological diagnosis were identified by a database 
search of the radiology and pathology reports at our 
institution. Medical records were reviewed to determine 
patient age, gender, initial presentation, medical history, 
grade of LG, means of tissue diagnosis, and treatment 
regimen.
Tissue diagnosis and grading of cases was based on the 
2008 WHO classification (11). In three of the patients, the 
diagnosis was made based on the surgical wedge resection 
of pulmonary nodules and masses. In one of the patients, 
the diagnosis was initially made by a liver biopsy, and 
pulmonary involvement was later confirmed at the autopsy. 
Two of the three patients also underwent FDG-PET 
scans prior to initiation of treatment. In one of these two 
patients, the initial PET scan was performed within three 
weeks of the chest CT. The follow-up PET of this patient 
and all three of the PET studies of the other patient were 
performed by concurrent CT.
CT scans of the chest from 2001 to 2009 were performed 
on various multi-detector CT scanners. The CT parameters 
ranged from 120-140 kVp, 260 to 432 mA, and 2.5 to 5 mm 
slice thickness reconstruction; two of these patients had CT 
scans performed with automatic tube current modulation. 
All scans were performed with IV contrast. Images were 
reviewed in the lung, soft tissue, and bone windows. 
PET scans were performed 60 minutes after injection of 
approximately 15 mCi of F-18 FDG; tomographic images 
of the body from the neck to the proximal thigh were 
acquired in 3D mode on either a Siemens HR+ PET scanner, 
Siemens Biograph 64 (Siemens Medical Systems, Erlangen, 
Germany), or GE Discovery 64 PET/CT scanner (GE Medical 
Systems, Milwaukee, WI). Standardized uptake values (SUV) 
were determined as the maximum value within the lung 
tumors, as a function of body weight. PET and CT images 
were displayed and registered on a Siemens Multimodality 
Workstation using True-D imaging software.
CT scans were reviewed retrospectively by two board-
certified, fellowship-trained chest radiologists who were 
aware of the diagnosis of LG in these patients. Disagreements 
were resolved by consensus. Data recorded from the CT 
scans included the number and size range of the lung 
nodules or masses. The presence of cavitation or central air 
density, central low attenuation defined as < 20 Hounsfield 
unit, air bronchograms, ground-glass halo, and peripheral 
enhancement of the nodule or masses was recorded. Other 
findings such as ground-glass opacities, interlobular 
and intralobular septal thickening, consolidation, 
lymphadenopathy, and pleural effusions were also recorded. 
The axial (peribronchovascular, subpleural, or random) and 
craniocaudal (upper, mid, lower) distribution of the disease 
was documented. Follow up CT scans were also reviewed 
Table 1. Demographics, Clinical Presentation, and Disease Course
Patient Age Gender Presentation Treatment Disease Course
1 51 Male Left pleuritic chest pain R-CHOP, methotrexate Responded to treatment, in remission 1 
  1/2 years after initial diagnosis
2 58 Male Rash, vision changes 
  (pulmonary findings 
  incidental on CXR)
R-CHOP Responded to treatment, developed
  pancreatic cancer with liver
  metastases 
3 39 Male Cough, dyspnea Rituximab Progression, died of pneumonia and 
  respiratory failure
4 60 Male Fever, weight loss, 
  night sweat
Interferon followed by EPOCH, 
  then Rituximab. 
  stem cell transplant
Progression, died of pneumonia and 
  respiratory failure
Note.— CXR = chest X-ray, EPOCH = Etoposide, Prednisone, Vincristine (Oncovin), Cyclophosphamide, Doxorubicin 
(Hydroxydoxorubicin), R-CHOP = Rituximab-Cyclophosphamide, Doxorubicin (Hydroxydoxorubicin), Vincristine (Oncovin), Prednisone Korean J Radiol 12(6), Nov/Dec 2011 kjronline.org 673
CT and FDG-PET Findings of Lymphomatoid Granulomatosis
to determine if there was a response to treatment. In 
cases where FDG-PET was performed, activity within the 
nodules was assessed in conjunction with a board certified, 
fellowship-trained nuclear medicine physician. Because 
of the small number of patients in the study, statistical 
analyses were not warranted.
RESULTS
Patient demographics, clinical presentations, and disease 
course are as summarized in Table 1. The mean age of the 
patients was 52 year old. All four patients were men. No 
affected patients were immunocompromised. Patient 3 
had a history of congenital deafness. Clinical presentation 
ranged from relatively mild respiratory symptoms to highly 
symptomatic systemic manifestations. All patients in our 
series were treated with chemotherapy. Two of the patients 
responded to chemotherapy, whereas two of the patients 
had progressive disease.
The pathological diagnosis of LG was made based on a 
surgical biopsy specimen. Three of the patients had CT-
guided percutaneous needle aspirate/biopsy of the lung 
nodules/masses, which did not result in the specific 
diagnosis of LG prior to surgical biopsy. Patient 1 had a 
histological grade of 2, patient 2 had a histological grade of 
3, and patients 3 and 4 had histological grades of 1 which 
eventually progressed to grade 3.
The main findings on chest CT are as summarized in Table 
2. Selected pertinent images of each patient are included 
in Figures 1-4. Pulmonary nodules and masses seen in all 
of the patients, multiple nodules and masses seen in three 
of the patients, and solitary nodules and masses in one 
of the patients. The nodules and masses were lower-lobe 
predominant with a peribronchovascular and/or subpleural 
distribution in the axial plane. 
All four of the patients had nodules or masses that 
demonstrated peripheral enhancement, central low 
attenuation, and ground-glass halo. Air-bronchograms were 
present in three patients, whereas cavitary nodules/masses 
were present in two patients.
Avid FDG uptake was present in both patients (patient 1 
and 2) who had FDG-PET (Figs. 1, 2). Nodules and masses 
larger than 2 cm in both patients demonstrated a paucity of 
central FDG uptake. For patient 1, the maximum SUV within 
the pulmonary nodules/masses at baseline was 7.3; whereas, 
the maximum SUV within pulmonary nodules/masses on 
follow up scan (58 days later) had decreased to 3.5 post 
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treatment. For patient 2, the maximum SUV within the 
pulmonary nodules/masses at baseline was 10.8; whereas, 
the maximum SUV within the pulmonary nodules/masses 
on post-treatment scan (39 days later) had decreased to 
4.3. FDG uptake was seen in the left chest wall mass and 
hepatic lesions of patient 1. No FDG avidity was present in 
mediastinal or hilar lymph nodes in either patient; even 
though patient 2 had mildly enlarged mediastinal nodes. 
DISCUSSION
Lymphomatoid granulomatosis is an angiodestructive EBV-
positive lymphoproliferative disease, which clinically and 
histologically, can mimic pulmonary lymphoma and Wegener 
granulomatosis (WG). Affected patients often present with 
non-specific symptoms such as cough, shortness of breath, 
chest pain, and B symptoms (fever, weight loss, malaise) (2), 
as in our series. LG primarily affects the pulmonary system; 
however, it can also affect the skin (39% of cases), the 
nervous system (30% of cases), kidneys, liver, and GI tract 
(12). In our series, two of the four patients had hepatic 
involvement. In addition, affected patients are often 
immunocompromised (Wiskott-Aldrich syndrome, human 
immunodeficiency virus [HIV], or lymphoma) though none 
of them were immunocompromised in our study. Prognosis 
is poor with up to two of three of patients dying within the 
first year of diagnosis; typically due to secondary infection 
(12).
Gross pathological specimens are significant for centrally 
necrotic nodules. Angiodestructive and angioinvasive 
polymorphic lymphoid infiltration is common, and is 
composed mainly of lymphocytes (mainly reactive T-cells, 
A
C
B
D
Fig. 1. Chest CT and FDG-PET images of patient 1. 
A. Axial pre-contrast CT image demonstrates peribronchovascular pulmonary nodules/mass and small left pleural effusion. B. Axial post-contrast 
CT image shows peripheral enhancement and central low attenuation of nodules/mass. C. Axial CT image in lung window shows subtle ground-
glass halo of two left lower lobe nodules as well as ground-glass opacity in anterolateral aspect of right lower lobe mass. Air-bronchogram is 
noted in lateral left lower lobe nodule. Small peribronchovascular nodules are noted in right lower lobe. D. Axial FDG-PET image demonstrates 
peripheral FDG uptake in pulmonary nodules/mass.Korean J Radiol 12(6), Nov/Dec 2011 kjronline.org 675
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with varying numbers of large atypical B-cells), plasma 
cells, and histiocytes. The relative number of the neoplastic 
large B-cells and degree of cytological atypia are the 
basis for the 3-tier grading system in LG. Histological 
grading of LG has important ramifications for management 
and prognosis (13). Grade 1 lesions are composed of a 
polymorphous lymphoid infiltrate with few large neoplastic 
B cells and without necrosis. Grade 2 lesions are composed 
of more frequent large neoplastic B cells in a polymorphic 
background with some areas of necrosis. Grade 3 lesions are 
composed of numerous large neoplastic B cells that form 
sheets with extensive necrosis and is treated as a large 
B-cell lymphoma (13). Our patients had varying histological 
grades; ranging from 1-3. Two patients showed grade 1 
A
C
E
B
D
Fig. 2. Chest CT and FDG-PET images of patient 2. 
A, B. Axial CT images in lung windows demonstrate peribronchovascular 
nodules with subtle ground-glass halos. Left lower lobe nodule shows 
central cavitation and internal air-bronchogram. C. Axial CT image in 
soft tissue window demonstrates peripheral enhancement and central 
low attenuation of nodules. D. Axial non-contrast CT performed two 
weeks after images A-C shows rapid enlargement of nodules. This also 
confirms that peripheral enhancement seen on prior CT was not due 
to intrinsic hyperdensity. E. Axial images from FDG-PET demonstrates 
peripheral FDG uptake within pulmonary nodules.Korean J Radiol 12(6), Nov/Dec 2011 kjronline.org 676
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A B
Fig. 3. Contrast-enhanced chest CT of patient 3. 
A. Axial image in soft tissue window demonstrates multiple pulmonary nodules and masses with peripheral enhancement and central low 
attenuation. Mass in right lower lobe is cavitary. B. Axial image in lung window demonstrates presence of air-bronchogram and ground-glass halo 
(arrows) of some nodules. Nodules and masses are distributed along bronchovascular bundle and in subpleural region.
A
C
B
D
Fig. 4. Pathology of lymphomatoid granulomatosis of patient 3. 
A. Initial biopsy showed grade 1 histology, with only isolated large neoplastic cells (arrows) in predominant background of small lymphocytes 
(Hematoxylin & Eosin staining). B, C. Sparse neoplastic cells are positive for B-cell marker CD20 (B, immunostain for CD20) and for Epstein-Barr 
virus (EBV) (arrow) (C, Epstein-Barr encoded RNA in situ hybridization). D. In subsequent biopsy, EBV-positive neoplastic cells are more frequent, 
concurrent with progression to grade 3 histology (Epstein-Barr encoded RNA in situ hybridization).Korean J Radiol 12(6), Nov/Dec 2011 kjronline.org 677
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histology, which eventually progressed to grade 3 histology.
Many of the findings in our study are similar to those 
previously reported in the radiology literature (3, 4, 7-9, 
14). As in other studies, our patients had pulmonary 
nodules or masses, with a lower lung preponderance. In 
addition, most of the cases in our series demonstrated 
a peribronchovascular preponderance of pulmonary 
nodules as described in the only other series studying 
the CT appearance of pulmonary LG (7). The propensity of 
pulmonary LG in our study to affect peribronchovascular and 
subpleural regions, which corresponds to a perilymphatic 
distribution, is as expected for a lymphoproliferative 
disorder. Internal air bronchograms in nodules and masses, 
seen in three of our patients with LG, also has also been 
described previously (7). An air-bronchogram has also been 
described in the setting of infection, with bronchogenic 
lung cancer (typically bronchioloalveolar cell carcinoma) (8, 
9, 14, 15), lymphoma, and WG (16-19). A low attenuation 
center and central cavitation of nodules/masses, seen 
in our study, has also been previously reported (3), and 
correspond to the histological findings of central necrosis.
To our knowledge, the ground-glass halo and peripheral 
enhancement of pulmonary nodules and masses have 
not been specifically described in LG. Initially described 
in angioinvasive aspergillosis (17), ground-glass halo 
was thought to represent a specific finding. Many other 
conditions have now been associated with this CT 
manifestation (20). Pathologically, the surrounding halo 
of ground-glass opacities may represent hemorrhage, 
inflammation, or tumor spread. Three out of four patients 
in our series had nodules or masses demonstrating the 
halo sign. Given LG’s angioinvasive nature, the areas of 
ground-glass surrounding nodules or masses likely represent 
hemorrhage. Peripheral enhancement of the nodules/masses 
was seen in all of the patients in our study in the majority 
of nodules and masses. The peripheral enhancement is also 
likely related to the angio-invasive and angio-destructive 
nature of the LG. 
A high index of suspicion for LG based on the combination 
of CT findings may have significant implications in further 
work-up and management of patients. In our series, the 
final diagnosis of LG in all four cases was made based on a 
surgical biopsy or autopsy specimen. Three of four patients 
underwent a CT-guided core needle biopsy, which did not 
yield the specific diagnosis of LG, possibly due to largely 
necrotic centers of these lesions. In addition, suspicion 
based on CT findings can also help guide and prompt 
specific immuno-staining for B-cell lymphocyte markers and 
in situ hybridization of EBV encoded RNA (EBER) to aid the 
diagnosis of this rare entity (Fig. 5).
All previously described cases of FDG PET in the setting of 
LG have shown increased uptake in pulmonary nodules and 
masses (8, 9, 14, 15). Only in one case report is there a 
suggestion of peripheral uptake in the walls of the cavitary 
pulmonary lesions (14). Nodules and masses larger than 
2 cm in our study demonstrated the paucity of central 
FDG uptake, consistent with the histological finding of 
central necrosis. After treatment, the maximum SUV within 
the pulmonary nodules/masses decreased, suggesting a 
response to treatment.
Coarse linear opacities described by Lee et al. (7) were 
not a major finding in our series. Though never explicitly 
stated, the linear opacities in their series may have 
represented a healing phase of nodules and masses as 
coarse linear opacities that became more prominent with 
the treatment of pulmonary LG in one of their patients. 
The CT scans included in our study were performed within 
two weeks of pathological diagnosis; Lee et al. (7) may 
have been more inclusive in the CT scans they included if 
the timing of imaging relative to pathological diagnosis in 
their series had been reported. Also, the reverse halo sign 
(central focus of ground-glass opacity surrounded by a rim 
of consolidation) has also been described in the setting of 
pulmonary LG (21). None of our cases demonstrated this 
unusual finding.
Pulmonary LG shares many of the same imaging 
manifestations of more common pulmonary conditions 
such as WG and pulmonary lymphoma, and should be 
considered when these more common diagnoses have 
Fig. 5. Contrast-enhanced chest CT of patient 4. Axial image 
demonstrates solitary nodule in posterior costophrenic right lower lobe 
with peripheral enhancement and central low attenuation.Korean J Radiol 12(6), Nov/Dec 2011 kjronline.org 678
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been excluded. This is especially true in patients with 
underlying immunosuppression (Wiskott-Aldrich syndrome, 
HIV, or lymphoma) as well as in patients with concomitant 
brain lesions. The combination of lower lung predominant 
peribronchovascular or subpleural pulmonary nodules and 
masses with central low attenuation, ground-glass halo, 
and peripheral enhancement should prompt consideration of 
this rare entity.
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